Triple threat: new combo therapy targets rare lung cancer
NCT ID NCT03760575
First seen Jan 04, 2026 · Last updated May 21, 2026 · Updated 27 times
Summary
This early-phase trial is testing whether adding the immunotherapy drug pembrolizumab and a special image-guided surgery to standard chemotherapy is safe and works for people with malignant pleural mesothelioma, a rare cancer of the lung lining. About 20 adults with measurable tumors will receive the combination treatment. The main goal is to check for side effects, while also tracking how long people live without the cancer growing and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESOTHELIOMAS PLEURAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Abramson Cancer Center of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.